Valsartan Bellwether Lawsuit Over Cancer Caused by Recalled Blood Pressure Drug Set for September 8, 2025
Parties will meet with the MDL judge today, to discuss issues scheduling the remaining bellwether trials selected by the Court.
Tag Archives: Irbesartan
-
-
Valsartan Liver Cancer Lawsuit Selected for First Jury Trial in MDL
First bellwether trial in the valsartan MDL will involve claims brought by an Alabama man diagnosed with liver cancer, which is the most commonly reported injury caused by the recalled blood pressure drug.
-
Valsartan Cancer Lawsuits To Be Set for First Bellwether Trial, Instead of Third-Party Payor Claim
More than 1,270 Valsartan lawsuits are currently awaiting trial, most involving plaintiffs diagnosed with cancer following exposure to the recalled blood pressure drug, who are getting sicker and many are dying.
-
Sanctions Imposed in Valsartan Recall Lawsuits Over Drug Maker’s Discovery Violations
Judge hopes Valsartan recall lawsuit sanctions over discovery failures will serve as a deterrent to other foreign companies considering disregard for U.S. laws.
-
More Than 1,200 Valsartan Lawsuits Pending in MDL Over Cancers Caused By Recalled Blood Pressure Drug
A joint report recommends that the first valsartan recall lawsuit be set to go before a jury in Fall 2024, after a prior trial scheduled to begin in March was postponed when the judge presiding over the litigation retired.
-
Valsartan Settlements Reached To Resolve Personal Injury, Class Action and Medical Monitoring Claims Against Hetero
Lawyers will seek preliminary approval for a settlement of valsartan lawsuits against the generic drug maker Hetero, but claims involving other manufacturers of contaminated valsartan pills remain unresolved
-
Valsartan Injury Lawyers To Meet With U.S. District Judge Recently Appointed To Preside Over Litigation
Parties indicate they have reached a proposed settlement agreement for certain Valsartan class action lawsuits and claims involving a similar drug, irbesartan.
-
Extended Use of Valsartan and Other Angiotensin-Receptor Blockers May Increase Cancer Risk: Study
Data from more than a dozen clinical trials suggest long-term Valsartan use may increase the risk of lung cancer after only two years of use.
-
Lupin Irebesartan Recall Issued Over Cancer Causing N-nitrosoirbesartan Contamination
-
New Irbesartan Recalls Announced Abroad Raising Concerns About New “Sartan” Contaminant: Azido
